3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pain
6
Neoplasms
6
Cancer Pain
6
Pain, Intractable
2
Multiple Myeloma
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia, Biphenotypic, Acute
2
Leukemia
2
Waldenstrom Macroglobulinemia
1
Vesico-Ureteral Reflux
1
Ureteral Neoplasms
1
Thrombocythemia, Essential
1
Sigmoidal Tumour
1
Sezary Syndrome
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Polycythemia Vera
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Pain, Postoperative
1
Nephrolithiasis
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Mucositis
1
Monoclonal Gammopathy of Undetermined Significance
1
Interventions
Interferon-alpha
7
aldesleukin
6
Sunitinib
6
Radiotherapy
5
Nivolumab
5
Doxorubicin
5
Vincristine
4
Ipilimumab
4
Filgrastim
4
Dactinomycin
4
Chemotherapy, Adjuvant
4
Axitinib
4
cabozantinib
3
Sorafenib
3
Everolimus
3
Etoposide
3
Cyclophosphamide
3
temsirolimus
2
pembrolizumab
2
Ifosfamide
2
G250 monoclonal antibody
2
Fluorouracil
2
Carboplatin
2
Bevacizumab
2
vitespin
1
shark cartilage extract
1
pazopanib
1
lenvatinib
1
glutamic acid diethyl ester
1
cemiplimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Kidney Neoplasms
×
Morphine
×
Clear all
NCT06349668
2026-02-05
SMILe
University Hospital, Linkoeping
Phase 3
Recruiting
220 enrolled